InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
17,064.00
(
0.36%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.18
(
-0.45%
)
Bitcoin
63,884.31
(
-3.80%
)
Post# of 251587
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119467
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 116047

Friday, 06/22/2018 11:04:41 AM

Friday, June 22, 2018 11:04:41 AM

Post# of 251587
Alexo Therapeutics—>ANX Oncology—(private CD47 company):

https://www.businesswire.com/news/home/20180622005026/en

ALX Oncology is developing ALX148, a high affinity CD47 blocker currently in clinical development (https://www.clinicaltrials.gov/ct2/show/NCT03013218 ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up